JPRN-jRCT2080220920
未知
3 期
A long-term study of OPC-262 in patients with type 2 diabetes
概览
- 阶段
- 3 期
- 干预措施
- 未指定
- 疾病 / 适应症
- Patients with type 2 diabetes
- 发起方
- Otsuka Pharmaceutical Co., Ltd.
- 入组人数
- 100
- 最后更新
- 2年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •(1\) Type 2 diabetes patients with HbA1c above 6\.5% and below 10%
- •(2\) Patients who are capable of giving informed consent
- •(3\) Patients who are able to take contraceptive measures to avoid pregnancy of the patient or the patient's partner
排除标准
- •(1\) Patients with type 1 diabetes mellitus, patients with diabetes mellitus due to other specified drugs, mechanisms or diseases, and patients with gestational diabetes mellitus
- •(2\) Patients with a medical history of diabetic coma
- •(3\) Patients with poorly\-controlled hypertension
- •(4\) Patients with heart failure
- •(5\) Patients with a complication of active hepatitis or hepatic cirrhosis
- •(6\) Patients undergoing treatment of glomerular diseases other than diabetic nephropathy
- •(7\) Patients with a history or complication of malignant tumor
结局指标
主要结局
未指定
相似试验
未知
3 期
A long-term clinical study of OPC-262 in patients with type 2 diabetestype 2 diabetesJPRN-jRCT2080221847Otsuka Pharmaceutical Co., Ltd.175
未知
2 期
A Phase 2 Study of OPC-262 in Patients With Type 2 Diabetespatients with type 2 diabetesJPRN-jRCT2080220672Otsuka Pharmaceutical Co., Ltd.280
未知
3 期
ong-term co-administration study of OPC-262 in patients with type 2 diabetes mellitustype 2 diabetesJPRN-jRCT2080221215Otsuka Pharmaceutical Co., Ltd.
已完成
3 期
A Study of OPC-262 in Patients With Type 2 DiabetesType 2 DiabetesNCT01046318Kyowa Kirin Co., Ltd.100
未知
2 期
A long-term administration study of OPC-41061 in patients with autosomal dominant polycystic kidney disease (ADPKD) [Extension of study 156-04-001]Autosomal dominant polycystic kidney disease (ADPKD)JPRN-jRCT2080220665Otsuka Pharmaceutical Co., Ltd.17